| Elizabeth Dunkley-hughes, PHARMD | |
|
7 Kilton Rd, Bedford, NH 03110-6522 | |
| (603) 263-6577 | |
| Not Available |
| Full Name | Elizabeth Dunkley-hughes |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 7 Kilton Rd, Bedford, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306440599 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Dunkley-hughes, PHARMD 372 Timbertop Rd, New Ipswich, NH 03071-3019 Ph: (603) 291-0034 | Elizabeth Dunkley-hughes, PHARMD 7 Kilton Rd, Bedford, NH 03110-6522 Ph: (603) 263-6577 |
News Archive
Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).
Education for women is the most important factor for positively influencing the health of women and children, Indian President Pratibha Patil said on Saturday at a meeting in New Delhi of The Partnership for Maternal, Newborn & Child Health (PMNCH), IANS/Sify News reports. "Education is a powerful driver of health. The relationship between poverty, lack of education and limited access to health services, is well recognised," Patil said at the start of the two-day conference (11/13).
Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies, according to a new study by urologists and radiologists at the Jefferson Prostate Diagnostic Center and the Kimmel Cancer Center at Jefferson in Philadelphia.
Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.
› Verified 5 days ago
Dr. Falon Anne Kaspszak, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 209 Route 101, Bedford, NH 03110 Phone: 603-472-3919 Fax: 603-472-7448 | |
Kim Ahearn, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 209 Route 101, Bedford, NH 03110 Phone: 603-472-3919 Fax: 603-472-7448 | |
Laurie Keith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 258 Wallace Rd, Bedford, NH 03110 Phone: 603-472-5847 | |
Nicholas Driscoll, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 258 Wallace Rd, Bedford, NH 03110 Phone: 603-472-5847 | |
Mrs. Ronda Lee Hatin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5 Colby Ct, Bedford, NH 03110 Phone: 603-622-2320 | |
Mrs. Lori Ellen Connors, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 220 S River Rd, Bedford, NH 03110 Phone: 603-263-0062 | |
Ms. Narmin Pirmohamed, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8 Technology Dr, Bedford, NH 03110 Phone: 603-626-6200 |